3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
7
Pancreatic Neoplasms
4
Urinary Bladder Neoplasms
3
Ovarian Neoplasms
3
Hematologic Neoplasms
3
Breast Neoplasms
3
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Docetaxel
7
Trastuzumab
3
sargramostim
2
entrectinib
2
Radiotherapy
2
Polymerase Chain Reaction
2
Immunohistochemistry
2
Gene Expression Profiling
2
Fluorodeoxyglucose F18
2
Flow Cytometry
2
Erlotinib Hydrochloride
2
Biopsy
2
zanidatamab
1
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trastuzumab deruxtecan
1
tipifarnib
1
tanespimycin
1
pertuzumab
1
pembrolizumab
1
oncogene protein E7, Human papillomavirus type 16
1
entinostat
1
alectinib
1
aldesleukin
1
X-Ray Therapy
1
Vorinostat
1
Thalidomide
1
Taxes
1
Ritonavir
1
Quality of Life
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
pertuzumab
×
Genitourinary
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled